US News

U.S. Supreme Court rejects J&J appeal over Risperdal drug

Published by

By Lawrence Hurley WASHINGTON (Reuters) – The U.S. Supreme Court rejected a bid by Johnson & Johnson to overturn a $70 million jury verdict against the pharmaceutical company for its failure to warn about risks associated with off-label uses of its antipsychotic drug Risperdal. The court turned away the company’s appeal of a November 2019 ruling by the Superior Court of Pennsylvania that upheld the verdict in favor of a Tennessee man named Adam Yount, who was prescribed the drug at age 4 in 2003. A jury in the Philadelphia Court of Common Pleas in 2016 found that the company failed to warn You…

Read More

Facebook Comments

Check Also

How To Buy Gold, Silver, And Platinum Using Bitcoin

Purchasing precious metals today is easier than ever. ...